270 related articles for article (PubMed ID: 33321163)
1. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
2. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M; Schüller U; Hagel C; Saeger W
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
[TBL] [Abstract][Full Text] [Related]
3. The Role of T-box Transcription Factor in a Pituitary Adenoma Diagnostic Algorithm.
McDonald WC; McDonald KN; Helmer JA; Ho B; Wang A; Banerji N
Arch Pathol Lab Med; 2021 May; 145(5):592-598. PubMed ID: 32991684
[TBL] [Abstract][Full Text] [Related]
4. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
5. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
6. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
7. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors.
Mete O; Asa SL
Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227
[TBL] [Abstract][Full Text] [Related]
8. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
9. Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms.
Inomoto C; Tahara S; Oyama K; Kimura M; Matsuno A; Teramoto A; Osamura RY
Brain Tumor Pathol; 2021 Jul; 38(3):183-188. PubMed ID: 34269950
[TBL] [Abstract][Full Text] [Related]
10. Transcription Factor Immunohistochemistry in the Classification of Pituitary Neuroendocrine Tumor/Adenoma: Proposal in a Limited-Resource Setting.
Sood R; Chatterjee D; Dutta P; Radotra BD
Arch Pathol Lab Med; 2024 Feb; 148(2):178-189. PubMed ID: 37074863
[TBL] [Abstract][Full Text] [Related]
11. Overview of the 2017 WHO Classification of Pituitary Tumors.
Mete O; Lopes MB
Endocr Pathol; 2017 Sep; 28(3):228-243. PubMed ID: 28766057
[TBL] [Abstract][Full Text] [Related]
12. Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours.
Lenders NF; Chui J; Low J; Inder WJ; Earls PE; McCormack AI
Pituitary; 2022 Dec; 25(6):997-1003. PubMed ID: 36271964
[TBL] [Abstract][Full Text] [Related]
13. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
14. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
[TBL] [Abstract][Full Text] [Related]
15. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.
Nishioka H; Inoshita N; Mete O; Asa SL; Hayashi K; Takeshita A; Fukuhara N; Yamaguchi-Okada M; Takeuchi Y; Yamada S
Endocr Pathol; 2015 Dec; 26(4):349-55. PubMed ID: 26481628
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs.
Inoshita N; Yoshimoto T; Takazawa Y; Fukuhara N; Okada M; Nishioka H; Yamada S
Brain Tumor Pathol; 2023 Jul; 40(3):158-162. PubMed ID: 37072666
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and biomarker profile of pituitary adenohypophysial tumors.
Mete O; Cintosun A; Pressman I; Asa SL
Mod Pathol; 2018 Jun; 31(6):900-909. PubMed ID: 29434339
[TBL] [Abstract][Full Text] [Related]
18. Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma.
McDonald WC; Banerji N; McDonald KN; Ho B; Macias V; Kajdacsy-Balla A
Arch Pathol Lab Med; 2017 Jan; 141(1):104-112. PubMed ID: 27227698
[TBL] [Abstract][Full Text] [Related]
19. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary.
Lopes MBS
Acta Neuropathol; 2017 Oct; 134(4):521-535. PubMed ID: 28821944
[TBL] [Abstract][Full Text] [Related]
20. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
Mete O; Kefeli M; Çalışkan S; Asa SL
Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]